Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

(MedPage Today) — The FDA approved taletrectinib (Ibtrozi) — a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) — for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116021

Author :

Publish date : 2025-06-11 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

Tulane Scientist Resigns, Cites Censorship of Pollution and Disparities Research

Oncology Community Rallies, Rails Against ‘Draconian’ Budget Cuts for NIH, NCI

Related Posts

Allergic to Your Smartwatch? You’re Not Alone

‘Like You’ve Named Your New Form of Research the Best Ever’: What We Heard This Week

If Students Dream of Scrubs, We Will All Be Healthier

Oral Frostbite Injury Highlights Dangers of Recreational Nitrous Oxide Use

How menopause made York woman forget her name

Why Rob Lowe Wants More People to Join Cancer Clinical Trials

Allergic to Your Smartwatch? You’re Not Alone

‘Like You’ve Named Your New Form of Research the Best Ever’: What We Heard This Week

If Students Dream of Scrubs, We Will All Be Healthier

Oral Frostbite Injury Highlights Dangers of Recreational Nitrous Oxide Use

How menopause made York woman forget her name

Why Rob Lowe Wants More People to Join Cancer Clinical Trials

Fig trees may benefit climate by turning carbon dioxide into stone

What Will Medicare’s New Prior Authorization Model Target?

Categories

Archives